Champions Oncology, Inc. (CSBR) Fair Value 2026

CSBR · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.8 /10

32 fundamental signals · 5 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-27, Champions Oncology, Inc. (CSBR) trades at $5.02, versus a $0.58 median fair value across its 5 active models — 88.4% below the current price. QOC: 6.8/10. Value Trap Risk: 26/100 (LOW). 5/13 models active.

Key Facts

Ticker
CSBR
Price
$5.02
Quality Score
6.8/10
Value Trap Risk
26/100
Models Active
5/13
Last Updated
Strength: 5 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Champions Oncology, Inc. (CSBR) Undervalued or Overvalued in 2026?

According to CirclFi’s 5-model valuation engine, Champions Oncology, Inc. (CSBR) appears overvalued as of : the median of 5 independent fair value estimates is $0.58, 88.4% below the current price of $5.02. Estimates range from $0.19 to $1.01. CSBR scores 6.8/10 on fundamental quality and 26/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. CSBR’s -88.4% gap is wider than that market norm, and the Biotechnology sector median is -64.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Champions Oncology, Inc. Stock in 2026? →

What Fair Value Does Each Model Give CSBR?

5 Intrinsic Value Models vs. Current Price ($5.02)

Core Models (Unlocked)
Model Fair Value Upside
Ensemble · Low Conviction
 $0.58 -88.4%
Scenario · High Conviction
 $1.01 -79.9%
Unlock the Full Matrix

Access 3 additional models including Regime Cross-Sectional, Sentiment SOTP, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 5 Models →

Cancel anytime · No contracts · Instant access

What Is CSBR's Fair Value Range?

Spread across 5 independent models · $0.19 to $1.01

CirclFi's 5 active models place Champions Oncology, Inc. (CSBR) between $0.19 and $1.01 per share, a spread of 140% of the median. The median of that range — $0.58 — is the fair value CirclFi publishes for CSBR, against a current price of $5.02.

Low · Regime CrossHigh · First Chicago
$0.19median $0.58$1.01
Where the range comes from
Most bearish modelRegime Cross-Sectional$0.19
Most bullish modelFirst Chicago$1.01
Model agreement0 bullish · 5 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for CSBR. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on CSBR, not a CirclFi price target. How each model works →

What Is Champions Oncology, Inc. (CSBR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Champions Oncology, Inc.'s intrinsic value is estimated at $0.58. Trading at its current price of $5.02, the valuation engine raises significant caution: 5 of 5 models flag downside risk, projecting a median implied return of -88.4%.

What Do the Models Say About CSBR?

5 of 13 models are currently active for CSBR. All 5 active models suggest the stock trades above fair value. Taken together, their median fair value for CSBR is $0.58 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does CSBR Rank in Biotechnology?

Among 620 Biotechnology stocks, CSBR ranks #63 by Quality of Company score. CirclFi's QOC score of 6.8/10 evaluates 32 fundamental signals. A score of 6.8 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

Champions Oncology, Inc.'s positioning within the Biotechnology segment means that market exclusivity window plays an outsized role in fundamental analysis. The sector's unique characteristics — including breakthrough therapy designations — shape both the opportunity set and risk profile.

Is CSBR a Value Trap?

CirclFi's Value Trap algorithm assigns CSBR a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

5 of 13 models are active for Champions Oncology, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Champions Oncology, Inc. earns a quality score of 6.8/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

Models cluster within a tight range (+16.2% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CSBR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CSBR's 5 active models, average confidence is 34%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Champions Oncology, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

VNDAVanda Pharmaceuticals Inc.QOC 6.8OCULOcular Therapeutix, Inc.QOC 6.8QTTBQ32 Bio Inc.QOC 6.8XBIOXenetic Biosciences, Inc.QOC 6.7TNGXTango Therapeutics, Inc.QOC 6.8MDGLMadrigal Pharmaceuticals, Inc.QOC 6.7SRRKScholar Rock Holding CorporationQOC 5.5TTRXTurn Therapeutics Inc.QOC 4.8OSTXOS Therapies IncorporatedQOC 4.0EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: VNDA · OCUL · QTTB · XBIO · TNGX · MDGL · SRRK · TTRX · OSTX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CSBR?

6 companies across all industries closest to CSBR’s Quality of Company score of 6.8/10.

GRABGrab Holdings LimitedQOC 6.8PINEAlpine Income Property Trust, Inc.QOC 6.8DBDeutsche Bank AktiengesellschaftQOC 6.8BAFNBayFirst Financial Corp.QOC 6.8OBEObsidian Energy Ltd.QOC 6.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GRAB · PINE · DB · BAFN · OBE · NVDA

Where Does CSBR Sit in CirclFi's Biotechnology Rankings?

CSBR is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Champions Oncology, Inc.’s Valuation?

What is Champions Oncology, Inc.'s intrinsic value in 2026?

CirclFi puts Champions Oncology, Inc. (CSBR)'s intrinsic value at $0.58 — the median of 5 independent model estimates as of 2026-08-27, ranging from $0.19 to $1.01. The Quality of Company score is 6.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CSBR overvalued or undervalued right now?

At $5.02, 0 of 5 active models suggest CSBR may be undervalued, while 5 indicate potential overvaluation. The median of all 5 fair value estimates is $0.58, 88.4% below the current price of $5.02 — a consensus view that CSBR is overvalued. The assessment depends on which methodology best fits Champions Oncology, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.8 mean for CSBR?

Champions Oncology, Inc.'s QOC of 6.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CSBR?

CirclFi analyzes CSBR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 5 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on CSBR?

Of the 5 models currently active on CSBR, First Chicago is the most bullish at $1.01 per share, and Regime Cross-Sectional is the most bearish at $0.19. CirclFi's published fair value for CSBR is the median of that range, $0.58, not either extreme. The gap between the two ends equals 140% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is CSBR a value trap in 2026?

Champions Oncology, Inc.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 5-model valuation engine, Champions Oncology, Inc. (CSBR) has a median fair value of $0.58 — 88.4% below the current price of $5.02 — as of 2026-08-27.” Source: circlfi.com/stock/CSBR/ · Methodology
Primary sources for this CSBR valuation
  • Financial statements: Champions Oncology, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000771856) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CSBR as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 5 mathematical frameworks give you clarity on CSBR.

Unlock All 5 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for CSBR Unlock All 5 — $39/mo